Place of triclabendazole in the treatment of human hepatic fascioliasis.

Sporadic outbreaks of Fasciola hepatica have been reported in France, appro ximately 50 to 100 cases per year The most appropriate therapy remains to b e determined. Clinical cases - We report two cases of patients infected with F. hepatica The infection was successfully treated with a single oral dose of triclaben dazole (10 mg/kg of body weight). The first patient was a 35-year-old woman presenting pain in the right hypochondria, fever and a slight hypereosinop hilia, but with seropositivity for fascioliasis, hepatic nodules on radiolo gical imagery, and F. hepatica eggs in her feces. The second patient was a 23-year-old man who had traveled to Madagascar and stayed there a month bef ore admission. The initial clinical examination was normal, but the biologi cal results showed an important hepatic cytolysis and a positive serology f or a diagnosis of hepatic fascioliasis. The clinical tolerance of triclaben dazole was excellent for both of these cases and the follow-up state two mo nths after treatment was normal. Comments - According 50 our experience and that recently reported in the li terature, triclabendazole may be regarded as the drug of choice for the tre atment of human fascioliasis. (C) 1999 Editions scientifiques et medicales Elsevier SAS.